An Open-Label, Randomized, Crossover Study to the Dose Proportionality of RSG XR in Healthy Volunteers in Fasting Conditions

Trial Profile

An Open-Label, Randomized, Crossover Study to the Dose Proportionality of RSG XR in Healthy Volunteers in Fasting Conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 May 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
    • 01 May 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top